

References

I-79

1. Mozobil (plerixafor) injection for subcutaneous use [package insert]. Genzyme Corporation. Cambridge:MA. Revised 09/2023.
2. MICROMEDEX DrugDex Compendium® 2024. Plerixafor (Mozobil).
3. Clinical Pharmacology™ Compendia. 2024. Tampa FL: Gold Standard, Inc. Plerixafor.
4. NCCN: National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024. Plerixafor.
5. Haverkos BM, Huang Y, Elder P, et al. A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2017;52(4):561–566.
6. Yang X, Wan M, Yu F, et al. Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis. Exp Ther Med. 2019;18(2):1141–1148.
7. Bhamidipati, P. K., Fiala, M. A., Grossman, et. al. Results of a prospective randomized, open-label, noninferiority study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in combination with Plerixafor for autologous stem cell mobilization in patients with multiple myeloma and non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation. 2017;23(12): 2065-2069.
8. Badar T, Dhakal B, Szabo A, et al. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. Journal of Clinical Apheresis. 2019;34(6):686-691.

9. Plerixafor In: AHFS Drug Information Online Electronic Medical Library.
Bethesda, MD: American Society of Health-System Pharmacists. Updated November
20, 2012.